Skip to main content
. 2013 Aug 6;173(3):430–437. doi: 10.1111/cei.12140

Figure 2.

Figure 2

Effect of prime-boost bacille Calmette–Guérin (BCG)/DNAhsp65 in diabetes manifestations in non-obese diabetic (NOD) mice. Weight variation (a) and blood glucose (b) were measured once a week from weeks 11 to 29. BCG was administered on week 7; the prime-boost group was also vaccinated with pVAXhsp65 at week 9. Diabetes incidence through the weeks can be analysed in (c). Results are expressed as mean ± standard error of the mean. *P < 0·05 in comparison to the NOD group. The percentage of diabetic and non-diabetic mice at week 29 can be observed in (d) and P = 0·003.